JP2017534645A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534645A5
JP2017534645A5 JP2017525016A JP2017525016A JP2017534645A5 JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5 JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017525016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534645A (ja
JP6946184B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/075877 external-priority patent/WO2016075036A1/en
Publication of JP2017534645A publication Critical patent/JP2017534645A/ja
Publication of JP2017534645A5 publication Critical patent/JP2017534645A5/ja
Application granted granted Critical
Publication of JP6946184B2 publication Critical patent/JP6946184B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017525016A 2014-11-10 2015-11-06 抗pdgf−b抗体及び使用法 Expired - Fee Related JP6946184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192519 2014-11-10
EP14192519.8 2014-11-10
PCT/EP2015/075877 WO2016075036A1 (en) 2014-11-10 2015-11-06 Anti-pdgf-b antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2017534645A JP2017534645A (ja) 2017-11-24
JP2017534645A5 true JP2017534645A5 (esLanguage) 2018-12-06
JP6946184B2 JP6946184B2 (ja) 2021-10-06

Family

ID=51947140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525016A Expired - Fee Related JP6946184B2 (ja) 2014-11-10 2015-11-06 抗pdgf−b抗体及び使用法

Country Status (15)

Country Link
US (1) US10087246B2 (esLanguage)
EP (1) EP3218400A1 (esLanguage)
JP (1) JP6946184B2 (esLanguage)
KR (1) KR20170082520A (esLanguage)
CN (1) CN107148429B (esLanguage)
AR (1) AR102593A1 (esLanguage)
AU (1) AU2015345322A1 (esLanguage)
BR (1) BR112017009792A2 (esLanguage)
CA (1) CA2963723A1 (esLanguage)
IL (1) IL251286A0 (esLanguage)
MX (1) MX2017005975A (esLanguage)
RU (1) RU2017120361A (esLanguage)
SG (1) SG11201703426PA (esLanguage)
TW (1) TW201630934A (esLanguage)
WO (1) WO2016075036A1 (esLanguage)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
JP6787888B2 (ja) 2014-11-10 2020-11-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗il−1ベータ抗体及び使用方法
BR112017009790A2 (pt) 2014-11-10 2017-12-19 Hoffmann La Roche anticorpos direcionados ao anti-ang2 e métodos de uso
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 多重特異性抗体
EP3792279A3 (en) * 2015-07-29 2021-07-07 Allergan, Inc. Heavy chain only antibodies to ang-2
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP4126940A1 (en) 2020-03-30 2023-02-08 F. Hoffmann-La Roche AG Antibody that binds to vegf and pdgf-b and methods of use
AU2022210475A1 (en) * 2021-01-25 2023-08-10 Regeneron Pharmaceuticals, Inc. Anti-PDGF-B antibodies and methods of use for treating pulmonary arterial hypertension (PAH)
WO2025150482A1 (en) * 2024-01-08 2025-07-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules that bind pdgf-b and pdgf-d, and methods of use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
MXPA05007853A (es) 2003-01-24 2006-02-10 Applied Molecular Evolution Antagonistas de il-1 beta humana.
KR101501870B1 (ko) * 2003-08-27 2015-03-12 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
DE102004062361A1 (de) * 2004-12-10 2006-06-22 Cocreate Software Gmbh & Co. Kg Verfahren zur Ableitung von technischen Zeichungen aus 3D Modellen mit mindestens zwei kollidierenden 3D Körpern
NZ556029A (en) * 2004-12-21 2010-04-30 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
KR20150023957A (ko) 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
DK3495387T3 (da) * 2012-07-13 2021-11-08 Roche Glycart Ag Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme
WO2014074823A1 (en) * 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
KR20150082503A (ko) * 2012-11-09 2015-07-15 화이자 인코포레이티드 혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
PE20151807A1 (es) 2013-04-29 2015-12-02 Hoffmann La Roche Anticuerpos modificados de union a fcrn humano y metodo de utilizacion
CA2931986A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
JP6787888B2 (ja) 2014-11-10 2020-11-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗il−1ベータ抗体及び使用方法
BR112017009790A2 (pt) 2014-11-10 2017-12-19 Hoffmann La Roche anticorpos direcionados ao anti-ang2 e métodos de uso

Similar Documents

Publication Publication Date Title
JP2017534645A5 (esLanguage)
JP2017534646A5 (esLanguage)
JP2020062036A5 (esLanguage)
JP2017534644A5 (esLanguage)
JP2017537896A5 (esLanguage)
RU2017120360A (ru) Биспецифические антитела и способы их применения в офтальмологии
HRP20211528T1 (hr) Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
RU2017120358A (ru) Анти-il-1-бета антитела и способы их применения
HRP20191584T1 (hr) Anti-cd79b protutijela i načini uporabe
JP2020511947A5 (esLanguage)
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
RU2017120361A (ru) Антитела к pdgf-b и способы их применения
JP2020500538A5 (esLanguage)
JP2018537966A5 (esLanguage)
JP2014511179A5 (esLanguage)
JP2016512551A5 (esLanguage)
JP2019536806A5 (esLanguage)
HRP20200384T1 (hr) Humanizirana anti-tau(ps422) protutijela i načini uporabe
RU2020124153A (ru) Гуманизированные антитела к cd19 человека и способы их применения
JP2017504566A5 (esLanguage)
JP2011046732A5 (esLanguage)
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
RU2018101978A (ru) Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
JP2017528476A5 (esLanguage)
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti